"An open-label extension study of the long-term safety,tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)."

drug protocol number
116457
drug sponsor
GSK
drug study
Ambrisentan
drug trial site
King Fahad Medical City (Riyadh)
drug status
Terminated
drug phase